초록 ▼

● 건선 유사 피부염증의 억제 효과
- IL-23, imiquimod에 의해 유도된 건선유사 피부염증 동물모델 확립
- Mesenchymal stem cell (MSC)의 주입에 의한 건선유사 피부염증 억제를 동물모델에서 검증
● MSC가 CD4+ T세포에 미치는 영향
- MSC와 CD4+ T세포의 co-culture에 의한 CD4+T세포의 증식억제 효과 검증
- MSC와 CD4+ T세포의 co-cultrue에 의한 CD4+T세포의 Th1,Th2,Th17세포로의 분화억제 효과 검증
- MSC와 CD4

● 건선 유사 피부염증의 억제 효과
- IL-23, imiquimod에 의해 유도된 건선유사 피부염증 동물모델 확립
- Mesenchymal stem cell (MSC)의 주입에 의한 건선유사 피부염증 억제를 동물모델에서 검증
● MSC가 CD4+ T세포에 미치는 영향
- MSC와 CD4+ T세포의 co-culture에 의한 CD4+T세포의 증식억제 효과 검증
- MSC와 CD4+ T세포의 co-cultrue에 의한 CD4+T세포의 Th1,Th2,Th17세포로의 분화억제 효과 검증
- MSC와 CD4+ T세포의 co-culture에 의한 CD4+T세포의 Treg세포로의 분화 유도 검증
● MSC가 dendritic cell (DC)에 미치는 영향
- MSC는 DC의 maturation을 억제하고 DC의 CD4+ T cell의 활성 및 분화 조절 기능에 영향을 미침.
● MSC는 imiquimod에 의한 keratinocyte의 증식과 분화를 억제함.
● 건선 질환 동물 모델을 이용한 제대혈 줄기세포 투여 후 특징적인 임상증상이나 사망개체는 관찰되지 않았음
● 피하로 투여한 MSC는 병변장기 특이적으로 분포함이 확인되었으며, 일부 clearance 장기 이외에 다른 장기에는 분포하지 않음을 확인하였음.
● 제대혈 줄기세포의 반복투여 시 종양원성 시험결과 종양이 발견되지 않았음.
● GMP 시설 내 줄기세포의 생산
● IND 신청, 보완 및 승인

Abstract ▼

I. Aim of the research
○ Conventional treatment of psoriasis has short duration of effectiveness, inconvenient schedule for drug treatment, toxicity, and non-compliance, so the effectiveness of the treatment is relatively low
○ Recently developed biological drugs show more effect, but there is

I. Aim of the research
○ Conventional treatment of psoriasis has short duration of effectiveness, inconvenient schedule for drug treatment, toxicity, and non-compliance, so the effectiveness of the treatment is relatively low
○ Recently developed biological drugs show more effect, but there is no information about side effects on the long-term treatment of the drug and the cost is very high
○ Therefore, new drug for psoriasis is necessary for lower cost and more effective therapy for treatment of psoriasis
○ It is reported that mesenchymal stem cells (MSCs) can inhibit T cell proliferation and differentiation without HLA-matching
○ MSC has low immunological rejection, so it might be used for the treatment of autoimmune diseases, such as psoriasis
○ This study might provide important information for the treatment of autoimmune diseases using MSC

II. Content of the research
○ Establishment of mouse model of psoriasis and determination of inhibitory effect of MSC on psoriasis-like skin inflammation
○ Effect of MSC on inhibition of keratinocyte proliferation and differentiation
○ Determination of MSC number for inhibition of psoriasis-like skin inflammation
○ Effect of MSC on CD4+ T cell proliferation, and differentiation and dendritic cell maturation
○ Determination of distribution and oncogenic property of MSC after subcutaneous injection in a mouse model of psoriasis
○ Application and approval of IND

III. Experimental results
○ MSC inhibited psoriasis-like skin inflammation in mice
○ MSC inhibited TPA-induced skin inflammation in mice
○ Co-cultured DC with MSC can inhibit DC maturation
○ MSC inhibited T cell proliferation, Th17 cell differentiation and induced Treg cell differentiation
○ MSC inhibited expression of pro-inflammatory mediators from stimulated keratinocyte, and calcium- or imiquimod-induced keratinocyte differentiation
○ There was no particular symptom and death after subcutaneous injection of MSC in mice
○ MSC was detected in skin after subcutaneous injection and the cells were not detected 2 weeks after the injection in mice
○ MSC did not form cancer after repeated injection in mice
○ Production of MSC in GMP level plant, establishment of production method of MSC and application of IND for clinical trial

IV. Plan for application of experimental results
○ The results provide basic concept for use of MSC to treat autoimmune diseases, such as psoriasis
○ Toxicity test and development of production method of MSC for cell therapy will be helpful when MSC is used to treat immune diseases